NCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
Clinical Trials
13 trialsNCT05191472 2025-01-15
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
University of California, San Francisco
Phase 2 Terminated
NCT03267888 2024-09-04
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Emory University
Phase 1/2 Completed
NCT03848845 2024-04-09
DREAMM 4
GlaxoSmithKline
Phase 1/2 Completed
NCT03506360 2024-01-09
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT02906332 2023-08-22
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Hackensack Meridian Health
Phase 2 Terminated
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT02576977 2021-10-08
KEYNOTE 183
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT01953692 2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02579863 2021-07-20
KEYNOTE 185
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02289222 2019-11-05
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT02331368 2018-07-27
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed